Home › Alopecia › NCT06869252
Autologous Adipose Cells Therapy
RecruitingPhase 1/2
Who can join
Ages 21 to 80 · All sexes
Full eligibility criteria
Inclusion Criteria: 1. Outpatients who express interest in skin rejuvenation, and/or who are experiencing skin conditions, such as winkles, fine lines, loss of skin elasticity, skin pigmentation, scarring. 2. Outpatients who are experiencing hair loss or hair thinning 3. Provision of signed and dated informed consent form 4. Clearly stated willingness to comply with all the procedures of the study and availability of the study 5. Female and Male aged between 21 to 80 years old 6 Medical clearance by family doctor Exclusion Criteria: 1. Pregnancy or lactation 2. Known allergic reaction to components of cell culture media 3. Chronic disease , e.g. cardiovascular disease, diabetes, chronic kidney disease, seizures 4. Chronic infections, e.g. skin fungi infection, psoriasis 5. Chronic wound healing 6. Currently taking hormone therapy 7. History of cancers and active cancers 8. Viral infection, e.g. HIV, hepatitis B, influenza, coronaviruses.
About the study
Autologous Adipose Cell Therapy is a series of process designated to address the demerits of the traditional autologous fat grafting and dermal fillers, while enhancing the versatility and aesthetic outcomes. In this study, the goal is to evaluate the safety and efficacy of Autologous Adipose cell Therapy for skin rejuvenation and hair improvement in human application.
What is being tested
- Autologous Adipose Cells Therapy (biological)
Sponsor: CERM INC. · Participants: 40 · Started: Aug 1, 2025
Contact the study team
- Ankeet Dixit · Phone: 813-992-2521
- Wing Nam Fung · Phone: 207-671-9370
Official record on ClinicalTrials.gov — NCT06869252
Locations in the U.S.
| Delaware | The Centre for Cosmetic Surgery & Medicine, Newark, Lewes The Centre for Cosmetic Surgery & Medicine, Newark |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.